Seres Therapeutics, Inc.

0.90 USD
-0.01 (-1.34%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Seres Therapeutics, Inc. stock is down -0.63% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Apr 15:11 19 Apr, 2024 2.00 PUT 200 10
09 May 19:17 21 Jun, 2024 1.00 CALL 8800 1690

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection. SER-155, a cultivated bacteria microbiome drug, is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases.

  • Oppenheimer
    Thu May 9, 12:49
  • Chardan Capital
    Wed May 8, 08:41